{"pmid":32429572,"title":"The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target.","text":["The Role of Lipid Metabolism in COVID-19 Virus Infection and as a Drug Target.","The current Coronavirus disease 2019 or COVID-19 pandemic has infected over two million people and resulted in the death of over one hundred thousand people at the time of writing this review. The disease is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Even though multiple vaccines and treatments are under development so far, the disease is only slowing down under extreme social distancing measures that are difficult to maintain. SARS-COV-2 is an enveloped virus that is surrounded by a lipid bilayer. Lipids are fundamental cell components that play various biological roles ranging from being a structural building block to a signaling molecule as well as a central energy store. The role lipids play in viral infection involves the fusion of the viral membrane to the host cell, viral replication, and viral endocytosis and exocytosis. Since lipids play a crucial function in the viral life cycle, we asked whether drugs targeting lipid metabolism, such as statins, can be utilized against SARS-CoV-2 and other viruses. In this review, we discuss the role of lipid metabolism in viral infection as well as the possibility of targeting lipid metabolism to interfere with the viral life cycle.","Int J Mol Sci","Abu-Farha, Mohamed","Thanaraj, Thangavel Alphonse","Qaddoumi, Mohammad G","Hashem, Anwar","Abubaker, Jehad","Al-Mulla, Fahd","32429572"],"abstract":["The current Coronavirus disease 2019 or COVID-19 pandemic has infected over two million people and resulted in the death of over one hundred thousand people at the time of writing this review. The disease is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Even though multiple vaccines and treatments are under development so far, the disease is only slowing down under extreme social distancing measures that are difficult to maintain. SARS-COV-2 is an enveloped virus that is surrounded by a lipid bilayer. Lipids are fundamental cell components that play various biological roles ranging from being a structural building block to a signaling molecule as well as a central energy store. The role lipids play in viral infection involves the fusion of the viral membrane to the host cell, viral replication, and viral endocytosis and exocytosis. Since lipids play a crucial function in the viral life cycle, we asked whether drugs targeting lipid metabolism, such as statins, can be utilized against SARS-CoV-2 and other viruses. In this review, we discuss the role of lipid metabolism in viral infection as well as the possibility of targeting lipid metabolism to interfere with the viral life cycle."],"journal":"Int J Mol Sci","authors":["Abu-Farha, Mohamed","Thanaraj, Thangavel Alphonse","Qaddoumi, Mohammad G","Hashem, Anwar","Abubaker, Jehad","Al-Mulla, Fahd"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32429572","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.3390/ijms21103544","keywords":["covid-19","sars-cov-2","coronavirus","endocytosis","lipid metabolism","sphingolipid"],"e_drugs":["Lipids"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667342288232120320,"score":9.490897,"similar":[{"pmid":32191676,"title":"Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity?","text":["Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity?","BACKGROUND: Viral infectivity depends on interactions between components of the host cell plasma membrane and the virus envelope. Here we review strategies that could help stem the advance of the SARS-COV-2 epidemic. METHODS AND RESULTS: We focus on the role of lipid structures, such as lipid rafts and cholesterol, involved in the process, mediated by endocytosis, by which viruses attach to and infect cells. Previous studies have shown that many naturally derived substances, such as cyclodextrin and sterols, could reduce the infectivity of many types of viruses, including the coronavirus family, through interference with lipid-dependent attachment to human host cells. CONCLUSIONS: Certain molecules prove able to reduce the infectivity of some coronaviruses, possibly by inhibiting viral lipid-dependent attachment to host cells. More research into these molecules and methods would be worthwhile as it could provide insights the mechanism of transmission of SARS-COV-2 and, into how they could become a basis for new antiviral strategies.","Acta Biomed","Baglivo, Mirko","Baronio, Manuela","Natalini, Giuseppe","Beccari, Tommaso","Chiurazzi, Pietro","Fulcheri, Ezio","Petralia, Paolo Pietro","Michelini, Sandro","Fiorentini, Giovanni","Miggiano, Giacinto Abele","Morresi, Assunta","Tonini, Gerolamo","Bertelli, Matteo","32191676"],"abstract":["BACKGROUND: Viral infectivity depends on interactions between components of the host cell plasma membrane and the virus envelope. Here we review strategies that could help stem the advance of the SARS-COV-2 epidemic. METHODS AND RESULTS: We focus on the role of lipid structures, such as lipid rafts and cholesterol, involved in the process, mediated by endocytosis, by which viruses attach to and infect cells. Previous studies have shown that many naturally derived substances, such as cyclodextrin and sterols, could reduce the infectivity of many types of viruses, including the coronavirus family, through interference with lipid-dependent attachment to human host cells. CONCLUSIONS: Certain molecules prove able to reduce the infectivity of some coronaviruses, possibly by inhibiting viral lipid-dependent attachment to host cells. More research into these molecules and methods would be worthwhile as it could provide insights the mechanism of transmission of SARS-COV-2 and, into how they could become a basis for new antiviral strategies."],"journal":"Acta Biomed","authors":["Baglivo, Mirko","Baronio, Manuela","Natalini, Giuseppe","Beccari, Tommaso","Chiurazzi, Pietro","Fulcheri, Ezio","Petralia, Paolo Pietro","Michelini, Sandro","Fiorentini, Giovanni","Miggiano, Giacinto Abele","Morresi, Assunta","Tonini, Gerolamo","Bertelli, Matteo"],"date":"2020-03-20T11:00:00Z","year":2020,"_id":"32191676","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.23750/abm.v91i1.9402","e_drugs":["Cyclodextrins","Cholesterol","Sterols","Lipids"],"topics":["Mechanism","Transmission"],"weight":1,"_version_":1666138490565296128,"score":487.0395},{"pmid":32457038,"title":"Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity.","text":["Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity.","The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the death of more than 328,000 persons worldwide in the first 5 months of 2020. Herculean efforts to rapidly design and produce vaccines and other antiviral interventions are ongoing. However, newly evolving viral mutations, the prospect of only temporary immunity, and a long path to regulatory approval pose significant challenges and call for a common, readily available and inexpensive treatment. Strategic drug repurposing combined with rapid testing of established molecular targets could provide a pause in disease progression. SARS-CoV-2 shares extensive structural and functional conservation with SARS-CoV-1 including engagement of the same host cell receptor (ACE2) localized in cholesterol-rich microdomains. These lipid-enveloped viruses encounter the endosomal/lysosomal host compartment in a critical step of infection and maturation. Niemann-Pick type C (NP-C) disease is a rare, monogenic neurodegenerative disease caused by deficient efflux of lipids from the late endosome/lysosome (LE/L). The NP-C disease-causing gene (NPC1) has been strongly associated with viral infection, as a filovirus receptor (e.g., Ebola) and through LE/L lipid trafficking. This suggests NPC1 inhibitors or NP-C disease mimetics could serve as anti-SARS-CoV-2 agents. Fortunately, there are such clinically approved molecules that elicit antiviral activity in pre-clinical studies, without causing NP-C disease. Inhibition of NPC1 may impair viral SARS-CoV-2 infectivity via several lipid-dependent mechanisms, which disturb the microenvironment optimum for viral infectivity. We suggest that known mechanistic information on NPC1 could be utilized to identify existing and future drugs to treat COVID-19.","J Lipid Res","Sturley, Stephen","Rajakumar, Tamayanthi","Hammond, Natalie","Higaki, Katsumi","Marka, Zsuzsa","Marka, Szabolcs","Munkacsi, Andrew","32457038"],"abstract":["The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the death of more than 328,000 persons worldwide in the first 5 months of 2020. Herculean efforts to rapidly design and produce vaccines and other antiviral interventions are ongoing. However, newly evolving viral mutations, the prospect of only temporary immunity, and a long path to regulatory approval pose significant challenges and call for a common, readily available and inexpensive treatment. Strategic drug repurposing combined with rapid testing of established molecular targets could provide a pause in disease progression. SARS-CoV-2 shares extensive structural and functional conservation with SARS-CoV-1 including engagement of the same host cell receptor (ACE2) localized in cholesterol-rich microdomains. These lipid-enveloped viruses encounter the endosomal/lysosomal host compartment in a critical step of infection and maturation. Niemann-Pick type C (NP-C) disease is a rare, monogenic neurodegenerative disease caused by deficient efflux of lipids from the late endosome/lysosome (LE/L). The NP-C disease-causing gene (NPC1) has been strongly associated with viral infection, as a filovirus receptor (e.g., Ebola) and through LE/L lipid trafficking. This suggests NPC1 inhibitors or NP-C disease mimetics could serve as anti-SARS-CoV-2 agents. Fortunately, there are such clinically approved molecules that elicit antiviral activity in pre-clinical studies, without causing NP-C disease. Inhibition of NPC1 may impair viral SARS-CoV-2 infectivity via several lipid-dependent mechanisms, which disturb the microenvironment optimum for viral infectivity. We suggest that known mechanistic information on NPC1 could be utilized to identify existing and future drugs to treat COVID-19."],"journal":"J Lipid Res","authors":["Sturley, Stephen","Rajakumar, Tamayanthi","Hammond, Natalie","Higaki, Katsumi","Marka, Zsuzsa","Marka, Szabolcs","Munkacsi, Andrew"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32457038","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1194/jlr.R120000851","keywords":["cholesterol","cholesterol/trafficking","dyslipidemias","ldl/metabolism","lipase/lysosomal","niemann-pick disease","sars-cov-2","storage diseases","coronavirus","drug repurposing","lysosomal storage disease","pandemic"],"e_drugs":["Cholesterol","Lipids"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668141322613030913,"score":423.0494},{"pmid":32344305,"pmcid":"PMC7177071","title":"A data-driven hypothesis on the epigenetic dysregulation of host metabolism by SARS coronaviral infection: Potential implications for the SARS-CoV-2 modus operandi.","text":["A data-driven hypothesis on the epigenetic dysregulation of host metabolism by SARS coronaviral infection: Potential implications for the SARS-CoV-2 modus operandi.","COVID-19, the disease caused by the novel SARS-CoV-2, a betacoronavirus structurally similar to SARS-CoV. Based on both structural and syndromic similarities with SARS-CoV, a hypothesis is formed on SARS-CoV-2 potential to affect the host's metabolism as part of its lifecycle. This hypothesis is evaluated by (a) exploratory analysis of SARS-CoV/human transcriptomic interaction data and gene set enrichment analysis (b) a confirmatory, focused review of the literature based on the findings by (a). A STRING Viruses (available search for human - SARS-CoV (NCBI taxonomy Id: 9606 vs. NCBI taxonomy Id: 694009) genomic interactions reveals ten human proteins, interacting with SARS-CoV: SGTA, FGL2, SPECC1, STAT3, PHB, BCL2L1, PPP1CA, CAV1, JUN, XPO1. Gene set enrichment analyses (GSEA) with STRING on this network revealed their role as a putative protein - protein interaction network (PPI; Enrichment p-value = 0.0296) mediating, viral parasitism, interleukin as well as insulin signaling, diabetes and triglyceride catabolism. In the literature, SARS-CoV has been known to cause de novo diabetes by ACE2-dependent uptake on pancreatic isle cells, and furthermore dysregulate lipid autophagy in favor of the viral lifecycle. Conversely, currently there are only non-causative, observational evidence of worse outcomes for COVID-19 patients with comorbid diabetes or hyperglycemia. No study has reported on the lipid profiles of COVID-19 patients; however, lipid-targeting molecules have been proposed as agents against SARS-CoV-2. Future studies, reporting on lipid and glucose metabolism of COVID-19 patients could help elucidate the disease's seculae and aid drug design.","Med Hypotheses","Vavougios, George D","32344305"],"abstract":["COVID-19, the disease caused by the novel SARS-CoV-2, a betacoronavirus structurally similar to SARS-CoV. Based on both structural and syndromic similarities with SARS-CoV, a hypothesis is formed on SARS-CoV-2 potential to affect the host's metabolism as part of its lifecycle. This hypothesis is evaluated by (a) exploratory analysis of SARS-CoV/human transcriptomic interaction data and gene set enrichment analysis (b) a confirmatory, focused review of the literature based on the findings by (a). A STRING Viruses (available search for human - SARS-CoV (NCBI taxonomy Id: 9606 vs. NCBI taxonomy Id: 694009) genomic interactions reveals ten human proteins, interacting with SARS-CoV: SGTA, FGL2, SPECC1, STAT3, PHB, BCL2L1, PPP1CA, CAV1, JUN, XPO1. Gene set enrichment analyses (GSEA) with STRING on this network revealed their role as a putative protein - protein interaction network (PPI; Enrichment p-value = 0.0296) mediating, viral parasitism, interleukin as well as insulin signaling, diabetes and triglyceride catabolism. In the literature, SARS-CoV has been known to cause de novo diabetes by ACE2-dependent uptake on pancreatic isle cells, and furthermore dysregulate lipid autophagy in favor of the viral lifecycle. Conversely, currently there are only non-causative, observational evidence of worse outcomes for COVID-19 patients with comorbid diabetes or hyperglycemia. No study has reported on the lipid profiles of COVID-19 patients; however, lipid-targeting molecules have been proposed as agents against SARS-CoV-2. Future studies, reporting on lipid and glucose metabolism of COVID-19 patients could help elucidate the disease's seculae and aid drug design."],"journal":"Med Hypotheses","authors":["Vavougios, George D"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32344305","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.mehy.2020.109759","keywords":["covid-19","diabetes","gene set enrichment analysis","sars-cov","sars-cov-2","triglycerides","viruses"],"e_drugs":["Glucose","Triglycerides","Lipids"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138495848022016,"score":415.2064},{"pmid":32461703,"pmcid":"PMC7243794","title":"Mechanobiology predicts raft formations triggered by ligand-receptor activity across the cell membrane.","text":["Mechanobiology predicts raft formations triggered by ligand-receptor activity across the cell membrane.","Clustering of ligand-binding receptors of different types on thickened isles of the cell membrane, namely lipid rafts, is an experimentally observed phenomenon. Although its influence on cell's response is deeply investigated, the role of the coupling between mechanical processes and multiphysics involving the active receptors and the surrounding lipid membrane during ligand-binding has not yet been understood. Specifically, the focus of this work is on G-protein-coupled receptors (GPCRs), the widest group of transmembrane proteins in animals, which regulate specific cell processes through chemical signalling pathways involving a synergistic balance between the cyclic Adenosine Monophosphate (cAMP) produced by active GPCRs in the intracellular environment and its efflux, mediated by the Multidrug Resistance Proteins (MRPs) transporters. This paper develops a multiphysics approach based on the interplay among energetics, multiscale geometrical changes and mass balance of species, i.e. active GPCRs and MRPs, including diffusion and kinetics of binding and unbinding. Because the obtained energy depends upon both the kinematics and the changes of species densities, balance of mass and of linear momentum are coupled and govern the space-time evolution of the cell membrane. The mechanobiology involving remodelling and change of lipid ordering of the cell membrane allows to predict dynamics of transporters and active receptors -in full agreement with experimentally observed cAMP levels- and how the latter trigger rafts formation and cluster on such sites. Within the current scientific debate on Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) and on the basis of the ascertained fact that lipid rafts often serve as an entry port for viruses, it is felt that approaches accounting for strong coupling among mechanobiological aspects could even turn helpful in better understanding membrane-mediated phenomena such as COVID-19 virus-cell interaction.","J Mech Phys Solids","Carotenuto, Angelo R","Lunghi, Laura","Piccolo, Valentina","Babaei, Mahnoush","Dayal, Kaushik","Pugno, Nicola","Zingales, Massimiliano","Deseri, Luca","Fraldi, Massimiliano","32461703"],"abstract":["Clustering of ligand-binding receptors of different types on thickened isles of the cell membrane, namely lipid rafts, is an experimentally observed phenomenon. Although its influence on cell's response is deeply investigated, the role of the coupling between mechanical processes and multiphysics involving the active receptors and the surrounding lipid membrane during ligand-binding has not yet been understood. Specifically, the focus of this work is on G-protein-coupled receptors (GPCRs), the widest group of transmembrane proteins in animals, which regulate specific cell processes through chemical signalling pathways involving a synergistic balance between the cyclic Adenosine Monophosphate (cAMP) produced by active GPCRs in the intracellular environment and its efflux, mediated by the Multidrug Resistance Proteins (MRPs) transporters. This paper develops a multiphysics approach based on the interplay among energetics, multiscale geometrical changes and mass balance of species, i.e. active GPCRs and MRPs, including diffusion and kinetics of binding and unbinding. Because the obtained energy depends upon both the kinematics and the changes of species densities, balance of mass and of linear momentum are coupled and govern the space-time evolution of the cell membrane. The mechanobiology involving remodelling and change of lipid ordering of the cell membrane allows to predict dynamics of transporters and active receptors -in full agreement with experimentally observed cAMP levels- and how the latter trigger rafts formation and cluster on such sites. Within the current scientific debate on Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) and on the basis of the ascertained fact that lipid rafts often serve as an entry port for viruses, it is felt that approaches accounting for strong coupling among mechanobiological aspects could even turn helpful in better understanding membrane-mediated phenomena such as COVID-19 virus-cell interaction."],"journal":"J Mech Phys Solids","authors":["Carotenuto, Angelo R","Lunghi, Laura","Piccolo, Valentina","Babaei, Mahnoush","Dayal, Kaushik","Pugno, Nicola","Zingales, Massimiliano","Deseri, Luca","Fraldi, Massimiliano"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32461703","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.jmps.2020.103974","keywords":["cell membrane","g-protein coupled receptors","gpcr","ligand-receptor","lipid rafts","mechanobiology","sars-cov-2","structured deformations"],"locations":["kinematics"],"e_drugs":["Cyclic AMP","Adenosine","Lipids"],"topics":["Mechanism"],"weight":1,"_version_":1668079521548468224,"score":347.81253},{"pmid":32227357,"title":"COVID-19 treatment by repurposing drugs until the vaccine is in sight.","text":["COVID-19 treatment by repurposing drugs until the vaccine is in sight.","Corona virus disease (COVID-19) has created pandemic in the world as declared by WHO on March 12, 2020. It is a viral disease caused by SARS-CoV 2 virus and has affected large populations in over 120 countries. There is no specific treatment available and management is empirical. Until such time that an effective vaccine is available for COVID-19 viral infection, one can repurpose known therapeutic drug molecules such as angiotensin receptor 2 blocker, a commonly used antihypertensive drug, to control COVID-19 virus from gaining entry into the host cell by blocking the angiotensin receptor. Clinical trials should also be undertaken to use statins, which are lipid-lowering drugs but have anti-inflammatory and immunomodulatory properties to prevent acute lung injury in COVID-19 infection.","Drug Dev Res","Phadke, Mrudula","Saunik, Sujata","32227357"],"abstract":["Corona virus disease (COVID-19) has created pandemic in the world as declared by WHO on March 12, 2020. It is a viral disease caused by SARS-CoV 2 virus and has affected large populations in over 120 countries. There is no specific treatment available and management is empirical. Until such time that an effective vaccine is available for COVID-19 viral infection, one can repurpose known therapeutic drug molecules such as angiotensin receptor 2 blocker, a commonly used antihypertensive drug, to control COVID-19 virus from gaining entry into the host cell by blocking the angiotensin receptor. Clinical trials should also be undertaken to use statins, which are lipid-lowering drugs but have anti-inflammatory and immunomodulatory properties to prevent acute lung injury in COVID-19 infection."],"journal":"Drug Dev Res","authors":["Phadke, Mrudula","Saunik, Sujata"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32227357","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1002/ddr.21666","e_drugs":["Lipids"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138492450635778,"score":346.2361}]}